Search results for "recurrence"

showing 10 items of 1036 documents

Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled…

2019

Background Patients with relapsed or refractory FLT3 internal tandem duplication (FLT3-ITD)-positive acute myeloid leukaemia have a poor prognosis, including high frequency of relapse, poorer response to salvage therapy, and shorter overall survival than those with FLT3 wild-type disease. We aimed to assess whether single-agent quizartinib, an oral, highly potent and selective type II FLT3 inhibitor, improves overall survival versus salvage chemotherapy. Methods QuANTUM-R is a randomised, controlled, phase 3 trial done at 152 hospitals and cancer centres in 19 countries. Eligible patients aged 18 years or older with ECOG performance status 0-2 with relapsed or refractory (duration of first …

AdultMale0301 basic medicinemedicine.medical_specialtyPopulationSalvage therapy/Gastroenterology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicinemedicineHumansBenzothiazoleseducationSurvival rateAgedQuizartinibSalvage Therapyeducation.field_of_studybusiness.industryPhenylurea CompoundsMiddle Agedmedicine.diseaseFludarabineSurvival RateTransplantationLeukemia Myeloid AcuteSettore MED/15 - MALATTIE DEL SANGUE030104 developmental biologyfms-Like Tyrosine Kinase 3OncologychemistryTandem Repeat Sequences030220 oncology & carcinogenesisCytarabineFemaleNeoplasm Recurrence LocalbusinessFebrile neutropeniamedicine.drug
researchProduct

Hepatitis C virus early kinetics and resistance-associated substitution dynamics during antiviral therapy with direct-acting antivirals

2018

The emergence of resistance-associated substitutions (RASs) can compromise the high efficacy of direct-acting antivirals (DAAs). Little is known about RASs selection at very early time points during DAA treatment. Therefore, we analyzed the potential emergence of RASs immediately after therapy initiation. Samples of 71 patients treated with different DAAs were collected at baseline, during therapy (hours 4 and 8; days 1-7; weeks 2-4) or until target not detected. HCV-RNA levels were determined by qPCR, and RASs were detected by deep sequencing. Sixty-three (89%) patients achieved a sustained virological response (SVR), 7 (10%) relapsed, and 1 (1%) experienced a breakthrough. Almost all non-…

AdultMale0301 basic medicinemedicine.medical_specialtySustained Virologic ResponseHepatitis C virusHepacivirusViral quasispeciesReal-Time Polymerase Chain ReactionDIRECT ACTING ANTIVIRALSmedicine.disease_causeAntiviral AgentsGastroenterologyDeep sequencingVirological response03 medical and health sciences0302 clinical medicineRecurrenceGenetic EvolutionVirologyInternal medicineDrug Resistance ViralHumansMedicineProspective StudiesSelection GeneticAgedAged 80 and overHepatologybusiness.industryAntiviral therapyvirus diseasesHepatitis C ChronicMiddle AgedViral Loaddigestive system diseases030104 developmental biologyInfectious DiseasesAmino Acid SubstitutionRNA ViralFemale030211 gastroenterology & hepatologySensitivity limitbusinessJournal of Viral Hepatitis
researchProduct

Recovery, relapse, or else? Treatment outcomes in gambling disorder from a multicenter follow-up study

2017

AbstractPurpose:Gambling disorder is associated with various adverse effects. While data on the immediate effectiveness of treatment programs are available, follow-up studies examining long-term effects are scarce and factors contributing to a stable therapy outcome versus relapse are under-researched.Materials and methods:Patients (n = 270) finishing inpatient treatment for gambling disorder regularly participated in a prospective multicenter follow-up study (pre-treatment, post-treatment, 12-month follow-up). Criteria for gambling disorder, psychopathology, functional impairment were defined as endpoints. Changes in personality were defined as an additional parameter.Results:At follow-up,…

AdultMale050103 clinical psychologymedicine.medical_specialtyAdolescentmedia_common.quotation_subjectProtective factorYoung Adult03 medical and health sciences0302 clinical medicineRecurrencemedicineHumansPersonality0501 psychology and cognitive sciencesProspective StudiesYoung adultPsychiatrymedia_commonExtraversion and introversion05 social sciencesConscientiousnessMiddle AgedAbstinenceNeuroticism030227 psychiatryPsychotherapyPsychiatry and Mental healthTreatment OutcomeGamblingFemalePsychologyFollow-Up StudiesPsychopathologyClinical psychologyEuropean Psychiatry
researchProduct

Establishment of standardised SLA/LP immunoassays: specificity for autoimmune hepatitis, worldwide occurrence, and clinical characteristics

2002

Background: Antibodies to soluble liver antigen/liver pancreas (SLA/LP) are specific markers of autoimmune hepatitis. Their target antigen has recently been cloned. Aims: To establish standardised immunoassays using the recombinant antigen, and to assess the frequency and significance of seropositivity in patients from different countries. Methods: An enzyme linked immunoassay was developed using purified recombinant antigen and validated by testing sera from 200 healthy blood donors and 1026 patients with various liver and non-liver diseases. The assay was then applied to 454 sera from 419 patients with autoimmune hepatitis from different countries. All sera were also tested by inhibition …

AdultMaleAdolescentEnzyme-Linked Immunosorbent AssayAutoimmune hepatitisSensitivity and Specificitylaw.inventionJapanMaintenance therapyAntigenRecurrencelawGermanymedicineHumansChildAutoimmune diseaseHepatitisbiologymedicine.diagnostic_testbusiness.industryLiver DiseasefungiHistocompatibility Antigens Class IHistocompatibility Antigens Class IIInfant NewbornGastroenterologyAntibodies MonoclonalInfantmedicine.diseaseRecombinant ProteinsUnited StatesHepatitis AutoimmuneTreatment OutcomeChild PreschoolImmunoassayImmunologybiology.proteinRecombinant DNAFemaleAntibodybusinessBiomarkersBrazilGut
researchProduct

Management of primary ameloblastoma of the jaw: a 15 years' experience.

2012

AIM: The aim of this retrospective study was to describe our 15-year experience in the management of primary ameloblastoma of the jaw. METHODS: We investigated 26 patients who had undergone surgical treatment for a single lesion, comprising six lesions of the maxillary bone and 20 tumors of the mandible: 73% had a radiolucent multilocular lesion; 23% a unicystic lesion; and 4% had an extraosseous form of the tumor. The smaller lesions (diameter <3 cm) were treated by conservative approaches; the larger lesions required radical surgical resection. Two groups were created according to whether the patients had received conservative or aggressive surgery. RESULTS: The recurrence rate was estima…

AdultMaleAdolescentEstheticsAge FactorsMiddle AgedPlastic Surgery ProceduresJaw NeoplasmsSettore MED/29 - Chirurgia MaxillofaccialeCurettageOsteotomyAmeloblastomaRadiographyYoung AdultTreatment OutcomeSettore MED/28 - Malattie OdontostomatologicheHumansFemaleNeoplasm Recurrence LocalChildameloblastoma general surgery surgery oralFollow-Up StudiesRetrospective StudiesMinerva stomatologica
researchProduct

Evaluation of the prognostic role of tumour-associated macrophages in newly diagnosed classical hodgkin lymphoma and correlation with early FDG-PET a…

2017

In Hodgkin Lymphoma (HL), about 20% of patients still have relapsed/refractory disease and late toxic effects rate continue to rise with time. 'Early FDG-PET' and tissue macrophage infiltration (TAM) emerged as powerful prognostic predictors. The primary endpoint was to investigate the prognostic role of both early FDG-PET and TAM; the secondary endpoint was to test if early FDG-PET positivity could correlate with high TAM score. A cohort of 200 HL patients was analysed. Induction treatment plan consisted of two to six courses of ABVD and, if indicated, involved field radiation therapy. All patients repeated CT scan and FDG-PET after two cycles and after the completion of therapy. TAM in di…

AdultMaleAdolescentHodgkin’s lymphomaMacrophagePrognosiAntigens Differentiation MyelomonocyticVinblastineDisease-Free SurvivalCohort StudiesBleomycinYoung AdultAntigens CDFluorodeoxyglucose F18RecurrencePositron Emission Tomography Computed TomographyAntineoplastic Combined Chemotherapy ProtocolsHumansCD68AgedAged 80 and overHodgkin's lymphomahematologyMacrophagesCD68; Hodgkin's lymphoma; macrophages; PET; prognosis; hematology; oncology; cancer researchAntibodies MonoclonalMiddle AgedPrognosisHodgkin DiseaseImmunohistochemistryDacarbazineTreatment OutcomePETDoxorubicinPositron-Emission Tomographyoncologycancer researchFemaleNeoplasm Recurrence LocalFollow-Up Studies
researchProduct

Life success of males on nonoffender, adolescence-limited, persistent, and adult-onset antisocial pathways: follow-up from age 8 to 42

2009

A random sample of 196 males, drawn from the Jyväskylä Longitudinal Study of Personality and Social Development, was divided into four groups of offenders using information from government registers of convictions between ages 21 and 47, from local police registers searched at age 21, from a Self-Report Delinquency Scale administered at age 36, from a Life History Calendar for ages 15-42, and from personal interviews at ages 27, 36, and 42. The groups were: persistent offenders (offences before and after age 21; 29% of the men); adolescence-limited offenders (offences before age 21; 27%); adult-onset offenders (offences after age 21; 16%); and nonoffenders (28%). The profile of the persiste…

AdultMaleAgingLongitudinal studymedicine.medical_specialtyAdolescentHuman Developmentmedia_common.quotation_subjectPsychology AdolescentPoison controlPersonality AssessmentCohort StudiesYoung AdultArts and Humanities (miscellaneous)RecurrenceAdaptation PsychologicalOdds RatioDevelopmental and Educational PsychologyJuvenile delinquencymedicineHumansPersonalityLongitudinal StudiesYoung adultChildSocial BehaviorPsychiatryLife StyleGeneral Psychologymedia_commonCriminal PsychologyAntisocial Personality DisorderNeuroticismMiddle ageJuvenile DelinquencyCrimePersonality Assessment InventoryPsychologyPersonalityAggressive Behavior
researchProduct

Risk factors for recurrence and incontinence after anal fistula surgery

2009

Objective: Fistula-in-ano continues to raise problems that require important therapeutic decisions. Our aim was to evaluate its recurrence and incontinence risk factors. Method: We analysed a series of 279 patients who had undergone anal fistula surgery with long-term follow-up. Results: 42.7% of the fistulae were considered complex and 46% had been referred from other institutions. There was delayed healing or recurrence in 7.2% patients, which appeared at a median of 4 months. The factors associated with recurrence were the type of fistula (extrasphincteric/suprasphincteric), nonidentification of internal opening (IO), recurrent or complex fistulae (CF), and associated chronic abscess. On…

AdultMaleAnal fistulamedicine.medical_specialtyMultivariate analysisbusiness.industryPatient SelectionFistulaGastroenterologyMiddle AgedFistulotomymedicine.diseaseSurgeryAge and genderRecurrencemedicineHumansRectal FistulaFemaleRisk factorbusinessDelayed healingDigestive System Surgical ProceduresFecal IncontinenceChronic abscessColorectal Disease
researchProduct

CEA and CA19-9 measurement as a monitoring parameter in metastatic colorectal cancer (CRC) under palliative first-line chemotherapy with weekly 24-ho…

2001

Summary Background There have been contradictory reports on the benefit of CEA and CA 19-9 measurements in patients with metastatic colorectal cancer using palliative chemotherapy. The object of this study was to examine the diagnostic accuracy of monitoring of palliative chemotherapy by means of CEA and CA19-9. Patients and methods The tumour markers CEA and CA 19-9 were subjected to serial measurement in patients with metastatic colorectal cancer (n = 90) using palliative first-line chemotherapy with weekly 24-hour infusion of high-dose 5-FU with FA and were compared with objective response according to WHO criteria. 85 patients could be evaluated. 43 patients (51%) initially had elevated…

AdultMaleAntimetabolites Antineoplasticmedicine.medical_specialtyPalliative careCA-19-9 AntigenColorectal cancerLeucovorinSensitivity and SpecificityGastroenterologyDrug Administration ScheduleFolinic acidCarcinoembryonic antigenRecurrenceInternal medicinemedicineHumansInfusions IntravenousAgedTumor markerbiologybusiness.industryPalliative CareHematologyMiddle Agedmedicine.diseaseChemotherapy regimenCarcinoembryonic AntigenSurgeryOncologyFluorouracilbiology.proteinFemaleCA19-9FluorouracilColorectal Neoplasmsbusinessmedicine.drugAnnals of Oncology
researchProduct

Obinutuzumab plus bendamustine in previously untreated patients with CLL: a subgroup analysis of the GREEN study

2017

GREEN (NCT01905943) is a non-randomized, open-label phase IIIb study investigating obinutuzumab alone or plus chemotherapy in chronic lymphocytic leukemia (CLL). We report a preplanned subgroup analysis of 158 previously untreated CLL patients receiving obinutuzumab–bendamustine (G-B). Patients received six 28-day cycles (C) of G-B: obinutuzumab day (D)1/D2 of C1 (25 mg D1/975 mg D2), 1000 mg D8 and D15 of C1, and D1 of C2–6; and bendamustine 70/90 mg/m2 D1 and D2 of C1–6. The primary endpoint was safety/tolerability. Grade ≥3 adverse events (AEs) occurred in 82.3% of patients, including neutropenia (49.4%), thrombocytopenia (12.0%) and febrile neutropenia (10.8%). Serious AEs included neut…

AdultMaleBendamustineCancer Researchmedicine.medical_specialtyNeoplasm ResidualNeutropeniaAntibodies Monoclonal HumanizedGastroenterologyArticle03 medical and health scienceschemistry.chemical_compound0302 clinical medicineObinutuzumabInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineBendamustine HydrochlorideHumansSurvival rateAgedAged 80 and overSalvage Therapybusiness.industryRemission InductionHematologyMiddle AgedPrognosismedicine.diseaseLeukemia Lymphocytic Chronic B-CellMinimal residual diseaseSurvival RateTumor lysis syndromeOncologyTolerabilitychemistryDrug Resistance Neoplasm030220 oncology & carcinogenesisFemaleNeoplasm Recurrence LocalRituximabbusinessFebrile neutropeniaFollow-Up Studies030215 immunologymedicine.drugLeukemia
researchProduct